Ocular GVHD: Eye Problems After BMT

Ocular GVHD (Graft-Versus-Host Disease) is an immune-mediated condition that develops after a bone marrow or stem cell transplant. Donor immune cells attack the tear glands and eye surface, causing dry eyes, burning, redness, and light sensitivity. Early specialist evaluation and treatment protect the eye surface and preserve vision long-term.

Ocular GVHD affects your eyes after a bone marrow or stem cell transplant. Donor immune cells target your tear glands and corneal surface. The condition can appear weeks, months, or even years after transplant. Early identification changes outcomes significantly.

This condition sits at the intersection of haematology and ophthalmology. Your transplant team and your eye doctor need to work together. Regular eye review is part of post-transplant care, not an optional extra.

What Is Ocular GVHD?

Graft-Versus-Host Disease (GVHD) is an immune-mediated inflammatory reaction. It occurs when donor immune cells recognise the recipient’s tissues as foreign and attack them. Several organs can be affected, including the skin, liver, gut, and eyes.

The eye is more commonly affected in chronic GVHD, but acute GVHD can also involve the ocular surface. When the eyes are involved, the condition is called Ocular GVHD.

What Are the Symptoms of Ocular GVHD?

Symptoms range from mild to severe. They include one or more of the following:

Dry eyes and a persistent gritty sensation
Burning and irritation
Redness
Excessive watering and tearing
Light sensitivity
Blurred or fluctuating vision

In children, obvious complaints are often absent. Parents may notice excessive eye rubbing, light sensitivity, or reluctance to open the eyes in bright light.

Do not dismiss vague symptoms such as discomfort, scratchiness, or eye fatigue. These can be early signs of ocular GVHD. Your transplant surgeon may request an eye evaluation even when you have no symptoms at all.

How Is Ocular GVHD Diagnosed?

A complete eye examination is the starting point. This includes visual acuity testing, refraction, slit-lamp examination, and tear film assessment.

Your eye doctor will also perform specific tests to evaluate the ocular surface. These include the Schirmer’s test, and staining of the cornea with fluorescein and/or Rose Bengal dyes. These tests assess tear production and identify surface damage not visible to the naked eye.

How Is Ocular GVHD Treated?

Management focuses on controlling dryness, reducing inflammation, preventing infection, and protecting the cornea from scarring.

Systemic drugs given by your bone marrow transplant team for the rest of the body often do not adequately treat the eyes. Your eye doctor will likely recommend one or more of the following:

Lubricating eye drops to improve comfort and reduce corneal damage
Steroid eye drops to control inflammation and prevent scarring
Antibiotic eye drops to prevent or treat secondary infection
Autologous serum eye drops to support healing of the ocular surface
Cyclosporine eye drops to reduce the immune-mediated reaction

Treatment is adjusted over time based on disease activity and symptom burden. This is a condition that needs long-term follow-up, not a single course of treatment.

How is Ocular GVHD Classified?

Acute ocular GVHD develops during or soon after systemic acute GVHD and is characterized by sudden inflammation, redness, pain, tearing, photophobia, and conjunctival involvement.

Chronic ocular GVHD is a long-term immune-mediated disease that typically presents with persistent dry eye, burning, grittiness, fluctuating vision, meibomian gland dysfunction, and progressive ocular surface damage.

Acute-on-chronic ocular GVHD occurs when a patient with established chronic ocular GVHD experiences a sudden inflammatory flare, causing a rapid worsening of symptoms such as redness, pain, light sensitivity, and ocular surface inflammation on top of their baseline chronic dry eye disease.

Who Is Most at Risk?

Anyone who has undergone a bone marrow or stem cell transplant can develop ocular GVHD. Risk is higher in:

Patients with chronic GVHD affecting other organs
Patients on prolonged immunosuppression
Those with a history of acute GVHD

Children who have had transplants are a particularly vulnerable group. Symptoms may be subtle. Eye problems can quietly affect reading, school performance, and daily comfort without an obvious complaint from the child.

When to See a Specialist

See an eye specialist promptly if any of the following apply.

You or your child has had a bone marrow or stem cell transplant, and eye symptoms have appeared at any point after — not only in the early weeks.

Symptoms are present but mild. Mild ocular GVHD does not stay mild without treatment. Surface damage accumulates quietly.

Your transplant team has not yet arranged an ophthalmic review. Ask for one. It should be part of standard post-transplant follow-up.

Vision feels “off” even though a recent check showed normal acuity. Tear film instability affects functional vision. Standard acuity testing does not capture it.

You have been given lubricants but the symptoms persist. This is a signal for specialist evaluation, not a reason to try a different brand of drops.

What Doctors Sometimes Miss

Ocular GVHD is underdiagnosed. Several patterns come up repeatedly in practice.

Symptoms labelled as “just dry eyes.” Post-transplant dryness is not routine dry eye. The mechanism is different, the severity is higher, and the risk of corneal scarring is real. It needs specialist evaluation, not over-the-counter drops.

Children who don’t complain. A child who rubs their eyes, squints, or avoids reading is not always being difficult. These are ocular surface symptoms. Parents and transplant teams both need to watch for them.

The quiet chronic phase. Acute GVHD gets attention. Chronic ocular GVHD can smoulder for months with low-grade symptoms. Vision may remain measurably normal while the surface continues to deteriorate. Symptom absence does not mean the eye is safe.

Delayed referral from transplant teams. Eye review is sometimes requested only after symptoms become severe. Baseline ophthalmic evaluation before or shortly after transplant is better practice. Earlier review means earlier intervention.

Ocular GVHD: Symptoms, Causes, and When to Worry

Symptom	What It Means	When to Worry
Dryness and grittiness	Tear gland damage from donor immune cells	If persistent or worsening despite lubricants
Burning and irritation	Ocular surface inflammation	If affecting daily activities, reading, or sleep
Redness	Conjunctival involvement	If sudden, severe, or accompanied by pain
Light sensitivity	Corneal surface damage	If debilitating or new after a settled period
Blurred or fluctuating vision	Tear film instability or corneal changes	Always warrants prompt specialist review
Eye rubbing in children	May be the only visible sign	If post-transplant, refer early — do not wait
Watering and tearing	Reflex response to surface dryness	If combined with other symptoms

FAQs

Can ocular GVHD occur without dry eye symptoms?

Yes. Some patients present with redness, light sensitivity, or blurred vision rather than classic dryness. In children, the only sign may be eye rubbing or reluctance to be in bright light. A specialist examination is more reliable than symptom-based self-assessment.

Does ocular GVHD go away on its own?

Occasionally it settles with time, but many patients need long-term treatment. Stopping treatment early often leads to flare-ups. Your eye doctor will guide when and how to taper any medications.

Can both eyes be affected?

Yes. Ocular GVHD typically affects both eyes, though one side may be more symptomatic than the other.

Is teleconsultation available for ocular GVHD follow-up?

Yes. If you live outside Gurgaon or are unable to travel, teleconsultation is available to support ongoing management in partnership with your local eye doctor.

This page is part of the Dry Eye Disease hub. Read about our full approach to GVHD, dry eyes, and children’s eye care. Please also read the Pediatric Eye Care hub.

Here’s another heartening patient story: A young boy and his love for trucks, and Chronic GVHD and Success Stories.

About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Read a patient story:

Ocular GVHD in Children

Chronic GVHD and Success Stories

Can Ocular GVHD Cause Dry Eyes?

Ocular GVHD is an eye condition that can develop after bone marrow or stem cell transplant, causing dry eyes, irritation, and fluctuating vision even after the main illness stabilises. Long-term follow-up helps protect the ocular surface, support daily function, and prevent slow, quiet damage from becoming permanent.

Here’s the story of a young girl’s grit and determination, as she battle GVHD. She is now a DOCTOR herself!!

She Came Back Every Holiday

A clinical story about ocular GVHD, dry eyes, and what it means to stay

Some patients stay in your memory because the diagnosis was rare.

Others stay because you realise, years later, that you were not just treating a condition. You were quietly watching somebody become who they were going to be.

I first met her when she was fifteen or sixteen. She had already been through more than most adults carry in a lifetime. She had undergone a bone marrow transplant. And afterwards, she developed ocular graft-versus-host disease — ocular GVHD.

Families who arrive after transplantation carry a particular kind of relief. The worst has happened. Treatment happened. Something enormous has been crossed. But uncertainty travels with them, because the body does not always stop at the finish line of the illness that was treated.

Then the eyes become part of the story.

What Ocular GVHD Feels Like From the Inside

Most people imagine ocular GVHD as something visibly dramatic. Sometimes it is. But for many patients, it arrives quietly.

Dryness that feels like something is always wrong, even on a good day. Burning that begins before the rest of the body feels tired. Vision that stays technically normal but no longer feels effortless.

Reading that becomes work. Studying that becomes slower. Screen time that was once easy and now costs something.

She was fifteen. She was trying to get back to school. She was trying to become a teenager again, the way teenagers are supposed to be — carelessly occupied with the future. And every day, her eyes made that harder.

Managing Ocular GVHD: What Actually Helps

Over the months that followed, we worked through treatment together. We managed her ocular surface carefully. We adjusted care as her symptoms changed. The active ocular GVHD gradually settled. Her vision got better. The comfort improved. Her reading improved. She got back to school.

But as so often happens with ocular GVHD, the story did not simply end when the acute phase resolved. She continued to have dry eyes. Frequent inflammation, sudden flare ups. Good months and difficult ones. The kind of low-grade, persistent vulnerability that does not make headlines but shapes ordinary days.

Steroids, in varying strengths, and frequency; lubricating eyedrops. Her BMT specialist and I, spoke about her thrice a day on some days, and some times, not even once a month.

She lived in Lucknow. Not nearby. And yet she kept coming back. Every few months. Then every holiday. Keeping in touch over the phone. Sometimes, just to talk. And we kept titrating her treatment to her symptoms, and to the disease activity.

Not because something dramatic was happening. Not because her vision was deteriorating. She came because follow-up had quietly become part of how she looked after herself. She understood, at sixteen, what many adults take years to learn: that a condition managed well is a condition you stop noticing.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google

What Patients Actually Remember

Doctors tend to think patients remember the treatment.

Patients usually remember something else. They remember whether someone recognised them the next time they walked in. They remember not having to explain everything from the beginning. They remember the quality of continuity more than the quality of any single intervention.

She sat her Class 12 examinations. Then she prepared for medical entrance exams.

One day she came to see me with her parents. Her eyes were stable. Her vision was good. She had come not because she needed treatment, but because she had received a medical school offer and wanted advice.

Which college. Which city. Whether to go far from home. We sat and talked. Years earlier we had been discussing tear films and corneal staining and drop regimens. Now we were discussing hostels and futures and what she wanted her life to look like.

She chose South India. She started medical school. Her parents were apprehensive because it was far away. Dr Shibal, she said, you can take care of me long distance, can’t you? I gave her a hug.

Your medical college will have an eye doctor, love. Yes, she said, but they’ll not be you.

And she still comes back. Every six months. Every holiday.

At one visit, she smiled and said something I still think about.

My vision is pristine.

I had to pause with that for a moment.

Because I do not think patients become doctors because someone cured them. I think sometimes they become doctors because someone stayed. Because someone showed them, over years of ordinary appointments, what it looks like to pay close attention to a person who is quietly carrying something.

This Is Not a Story About a Perfect Outcome

Her eyes still need looking after. She still struggles in difficult stretches. And is on medication. She still follows up.

But she built a life. She studied. And left home. She entered medicine. And every time she walks back into my clinic, I am reminded that the most important things in practice do not happen in the moments of diagnosis or surgery or crisis.

They happen in the reviews. The adjustments. The small, ordinary appointments where someone walks in and you already know who they are.

That is where medicine actually changes lives.

Last month, she graduated from medical school.

What Is Ocular GVHD?

Ocular graft-versus-host disease (ocular GVHD) is an eye condition that can develop after bone marrow or stem cell transplant. Donor immune cells may attack the tear glands and ocular surface, causing dryness, inflammation, and changes in visual comfort that persist long after the transplant itself has stabilised.

Symptoms can continue, fluctuate, or remain low-grade for years. Because of this, patients often benefit from long-term ophthalmic follow-up even when their systemic illness is well controlled and their measured vision remains good.

Symptoms of Ocular GVHD include:

Dry eyes, burning, irritation, fluctuating vision, redness, light sensitivity, watering, eye fatigue, difficulty reading or using screens for extended periods, and persistent ocular surface sensitivity that worsens with study, work, or environmental change.

How is Ocular GVHD classified?

Acute ocular GVHD develops during or soon after systemic acute GVHD and is characterized by sudden inflammation, redness, pain, tearing, photophobia, and conjunctival involvement.

When Should You See an Eye Specialist?

If you or your child has undergone a bone marrow or stem cell transplant and you notice persistent dryness, redness, fluctuating vision, burning, or discomfort — do not assume this is simply part of recovery.

The ocular surface can remain affected even after systemic disease feels far behind you. Early evaluation may preserve comfort, function, and long-term visual quality.

Known for her structured approach to vision risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online.

This page is part of the Dry Eye Disease hub . Read about our full approach to GVHD, Dry Eyes and children’s eye care. Please also read Pediatric Eye Care hub

Here’s another heartening patient story: A young boy and his love for trucks

FAQs:

What is ocular GVHD?

Ocular GVHD is a complication that can develop after bone marrow or stem cell transplant. Donor immune cells affect the tear glands and eye surface, causing dryness, inflammation, and visual discomfort that may persist long after the main transplant illness stabilises.

What are the common symptoms?

Dry eyes, burning, fluctuating vision, redness, irritation, light sensitivity, watering, difficulty reading, and visual fatigue that worsens with screens or study.

Can ocular GVHD improve over time?

Yes. Many patients improve significantly, particularly with consistent treatment and close follow-up. Some continue to experience low-grade dryness or surface sensitivity for years. This does not mean the condition is untreatable — it means it requires sustained attention rather than a single course of treatment.

Can patients with ocular GVHD study, work, and live normally?

Many can, particularly when symptoms are identified early and managed consistently. The goal of treatment is not only to protect vision but to restore the quality of everyday life — reading, screens, study, and all the things that ordinary days are made of.

Why is long-term follow-up important?

Symptoms and underlying ocular surface health do not always change in parallel. A patient may feel stable and still have ongoing surface changes that benefit from monitoring. Regular review allows treatment to be adjusted before problems compound.

Does ocular GVHD affect children and young people differently?

The condition affects children and adolescents at a time when study load, screen use, and daily reading demands are high. Symptoms that an adult might manage around can significantly affect a young person’s academic performance and sense of normalcy. Recognising this early changes what the follow-up plan should look like.

About the Author

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Ocular Graft Versus Host Disease in Children

Ocular GVHD (Graft-versus-Host Disease) can cause severe dry eyes, burning, fluctuating vision, light sensitivity, and damage to the eye surface after a bone marrow or stem cell transplant. Early diagnosis and long-term eye care may help protect comfort, vision, and quality of life.

Managing these cases requires specialised corneal expertise, strict protective isolation compliance, and a deeply trauma-informed approach to pediatric clinical examination. Scientific precision alone is not enough — the child must feel safe enough to let you in.

Beyond the Sterile Barrier: Pediatric Ocular Graft-Versus-Host Disease

There are moments in a pediatric ophthalmologist’s career that anchor you for life.

During my time at Fortis, I cared for a tiny boy fighting for his life after a bone marrow transplant. Severe, acute Ocular GVHD had left his corneas damaged, covered in countless microscopic raw spots — Superficial Punctate Keratitis — causing blinding pain and extreme light sensitivity. He lived in the ICU, unable to open his eyes, afraid of every sound.

His immune system was almost non-existent. Anyone entering his space had to be covered head to toe in sterile gowns and masks. He could not see my face. He was terrified. Some days, he was too weak to cry.

To help him recognise me without triggering fear, I started a routine. Every time I entered his isolation pod, I whistled softly. He learned quickly. The whistle meant safety. No needles. It meant the person coming was not going to hurt him.

I would apply a careful drop of anaesthetic to numb the intense surface pain just enough to let me examine his corneas and adjust his treatment. And I kept talking. Through every protocol, every follow-up, every barrier-gowned visit, a bond formed between us.

His parents would quietly hold him. Silently, patiently, with all the love in the world.

Can GVHD be cured?

That was the only question they asked. For the pain to go away. I would say yes, he will be fine. And pray, silently.

And then one day, instead of crying, he started talking. About trucks, and JCBs and construction. All of five. And bright. And happy. Like any other five year old.

The drops continued, but he was now walking into my OPD, showing off his toys, his jeans, his shoes which have red and blue lights. And one day, we didn’t need any medication at all.

Today, he is completely cured — a bright, healthy boy, a handful and a half. Goes to big school. And to Goa with his grandparents. Collects toy trucks, especially likes yellow ones.

When he walks into my clinic, he does not see masks or sterile gowns. He sees a friend. He spots me from across the waiting room and runs full tilt into my arms. And talks till my ears hurt. And my face hurts. From smiling so much.

His parents recently told me that when they return to his BMT hospital for follow-ups, he looked up at the first floor where my old OPD used to be and insisted: “Let’s go meet Dr Shibal.” They had to remind him gently that I have moved. When he visited me at Marengo Asia after that, he looked around the new clinic and said, with complete satisfaction: “Dr Shibal, you always own the first floor.”

He is entirely right. Just like he owns my entire heart.

PS: Two of his classmates have come to me to get their glasses checked. Apparently he tells everyone about “My doctor” who has a hundred toffees. My little advertising blitzkreig he is 🙂

FAQs

What is Ocular GVHD in children, and what are the symptoms?

Ocular GVHD occurs when donor immune cells after a bone marrow transplant attack the recipient’s lacrimal glands and corneal surface. In children, symptoms include severe eye pain, redness, a gritty sensation, extreme light sensitivity, and refusal to open the eyes due to corneal surface damage. Early specialist intervention is critical to prevent permanent scarring.

What are the most common symptoms of ocular GVHD in adults?

Symptoms may include dry eyes, burning, redness, watering, irritation, light sensitivity, fluctuating vision, eye fatigue, and a feeling of grit or sand in the eyes.

Can ocular GVHD affect vision permanently?

If untreated, ocular GVHD can lead to chronic surface damage, discomfort, and vision changes. Early treatment and regular follow-up may reduce the risk of long-term complications.

How is ocular GVHD diagnosed?

Diagnosis is based on symptoms, eye examination, tear film assessment, evaluation of the eye surface, and correlation with transplant history and systemic GVHD status.

What treatments are available for ocular GVHD?

Treatment may include preservative-free lubricants, medicines to reduce inflammation, tear conservation strategies, ocular surface support, and long-term monitoring depending on severity.

How is severe pain and photophobia managed in post-transplant pediatric patients?

Management is multi-layered and highly specialised. It includes preservative-free lubricants, autologous serum eye drops, therapeutic scleral or bandage contact lenses, and targeted topical immunomodulators. During acute flares, topical anaesthetics are used carefully during examination by the specialist — never for unsupervised home use — to allow assessment without causing further distress to the child.

This page is part of the Pediatric Eye Care hub. Read about our full approach to children’s ophthalmology. Please also read Dry Eye Disease

Here’s another heartening patient story: the young girl who is now a doctor herself!

About the Author

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Dry Eye Is Not Just Dryness: Managing It as a Chronic Condition

Dry eye disease is a chronic condition caused by an unstable or insufficient tear film. It does not go away with occasional lubricating drops. Left unmanaged, it causes progressive surface damage, worsening discomfort, and, in some cases, permanent corneal scarring. Long-term management, not short-term relief, is the correct approach, says Dr Shibal Bhartiya.

Dry eye is one of the most common eye conditions seen in clinical practice. Most patients manage it with over-the-counter drops and expect it to resolve. It rarely does.

Dry eye disease is a multifactorial condition of the ocular surface. The tear film is complex. When it breaks down, the result is inflammation, epithelial damage, and a cycle that perpetuates itself without targeted treatment.

Understanding dry eye as a chronic disease changes how patients manage it, and how much vision and comfort they can preserve over time.

What Is Dry Eye Disease?

Dry eye disease (DED) is defined by the TFOS DEWS II report as a multifactorial disease of the ocular surface. It involves loss of tear film stability and is accompanied by symptoms and signs of varying severity.

The tear film has three layers: a mucin layer anchoring tears to the eye surface, an aqueous (watery) layer providing nutrients and oxygen, and a lipid (or oil) layer produced by the meibomian glands that prevents evaporation. A problem in any one layer causes disease.

Two Main Types of Dry Eye

Aqueous Deficient Dry Eye

This type involves insufficient tear production. The lacrimal gland does not produce enough aqueous fluid. It is common in post-menopausal women, patients with Sjogren’s syndrome, and those on antihistamines, antidepressants, or blood pressure medications.

Evaporative Dry Eye

This is the more common type, accounting for roughly 85 percent of all dry eye cases. Meibomian gland dysfunction (MGD) is the primary cause. Blocked or abnormal meibomian glands fail to secrete a healthy lipid layer, and tears evaporate too quickly.

Many patients have both types simultaneously. Treatment must address the dominant mechanism.

Feature	Aqueous Deficient DED	Evaporative DED
Primary cause	Reduced lacrimal gland output	Meibomian gland dysfunction
Proportion of cases	Approximately 15%	Approximately 85%
Key risk factors	Sjogren’s, medications, age	Screen use, blepharitis, rosacea
Tear break-up time	Reduced	Very short (under 5 seconds)
Treatment focus	Tear supplementation	Lid hygiene, heat, omega-3
Inflammation present	Often yes	Yes, secondary

Why Dry Eye Becomes Chronic

The tear film and ocular surface exist in a feedback loop. When the tear film is unstable, the surface desiccates. This triggers inflammation. Inflammation damages goblet cells and lacrimal tissue. Damaged tissue produces less stable tears. The cycle continues.

Without breaking this cycle, not just lubricating the surface, dry eye worsens over months and years. This is why patients who only use drops often find their symptoms returning or intensifying.

Chronic untreated dry eye can cause corneal epithelial breakdown, punctate keratitis, subepithelial scarring, and, in severe cases, corneal ulcers. These are not trivial outcomes.

Risk Factors That Drive Progression

Screen use of more than four hours daily reduces blink rate and increases evaporation.
Contact lens wear disrupts the tear film and accelerates meibomian gland dropout.
Hormonal changes — especially menopause — reduce lacrimal and meibomian secretions.
Systemic medications including antihistamines, SSRIs, diuretics, and isotretinoin reduce tear production.
Autoimmune conditions such as rheumatoid arthritis, lupus, and thyroid disease affect the lacrimal gland.
Rosacea is a strong risk factor for meibomian gland dysfunction and is frequently undiagnosed.
Air conditioning, low humidity, and air travel accelerate tear evaporation.
Prior LASIK or refractive surgery causes corneal nerve damage and temporarily reduces reflex tearing.

How Dry Eye Is Diagnosed

Diagnosis requires more than a symptom questionnaire. A structured assessment includes the OSDI (Ocular Surface Disease Index) score, tear break-up time (TBUT), Schirmer’s test, corneal and conjunctival staining with fluorescein and lissamine green, and meibomian gland evaluation.

Meibography — infrared imaging of the meibomian glands — shows the degree of gland dropout and guides treatment intensity. Patients with significant gland loss need early and aggressive intervention to preserve remaining function.

Tear osmolarity testing measures the salt concentration of tears. Elevated osmolarity confirms tear film instability and is useful for monitoring treatment response objectively.

Diagnostic Test	What It Measures	Clinical Significance
TBUT (tear break-up time)	Tear film stability	Under 10 seconds is abnormal
Schirmer’s test	Aqueous tear production	Under 10 mm in 5 min is reduced
Corneal fluorescein staining	Epithelial surface damage	Confirms active disease severity
Meibography	Meibomian gland structure and dropout	Guides long-term prognosis
Tear osmolarity	Tear salt concentration	Over 308 mOsm/L confirms DED
OSDI score	Symptom burden	Tracks treatment response over time

Treatment: A Layered Approach

Dry eye treatment is not one-size-fits-all. It is matched to disease type, severity, and the dominant mechanism driving symptoms.

Step 1: Environmental and Behavioural Changes

Reduce screen time or use the 20-20-20 rule — every 20 minutes, look at something 20 feet away for 20 seconds. Increase blink frequency consciously. Use a humidifier in air-conditioned environments. Wear wraparound glasses in wind and dry air.

Step 2: Lid Hygiene and Warm Compresses

Warm compresses applied for 10 minutes daily soften meibomian secretions and improve gland expressibility. Lid massage after warming clears blocked glands. Lid scrubs with baby shampoo or commercially prepared wipes reduce bacterial load on the lid margin.

Consistency matters more than intensity. Daily lid hygiene over months produces measurable improvement in tear film quality.

Step 3: Lubricating Eye Drops

Not all lubricants are equivalent. Drops containing carboxymethylcellulose, sodium hyaluronate, or polyethylene glycol provide longer contact time. Preservative-free formulations are essential for patients using drops more than four times daily — preservatives accelerate the surface damage they are meant to relieve.

Gel formulations and ointments provide longer relief but blur vision temporarily and are best used at night.

Step 4: Omega-3 Fatty Acid Supplementation

Omega-3 supplements — particularly EPA and DHA from fish oil or re-esterified triglyceride formulations — improve meibomian secretion quality and reduce ocular surface inflammation. The DREAM study showed that high-dose omega-3 did not significantly outperform olive oil placebo, but clinical practice and other evidence support a role for supplementation in evaporative dry eye.

A daily dose of 2000 to 3000 mg EPA+DHA for at least three months is typically recommended.

Step 5: Anti-Inflammatory Therapy

When inflammation is driving symptoms, lubricants alone are insufficient. Cyclosporine eye drops (0.05% or 0.1%) reduce T-cell mediated inflammation on the ocular surface and restore goblet cell density over three to six months of use. They are not a quick fix — patients must be counselled on the time course.

Lifitegrast 5% is an integrin antagonist that blocks the LFA-1 to ICAM-1 interaction driving ocular surface inflammation. It offers symptom relief somewhat faster than cyclosporine.

Short-term topical corticosteroids are used to rapidly break the inflammatory cycle, particularly at disease onset or during flares. They are not for long-term use.

Step 6: Procedural Treatments

Intense Pulsed Light (IPL) therapy targets abnormal blood vessels on the lid margin that drive meibomian gland inflammation. It also applies heat that melts obstructed meibum. Multiple sessions spaced three to four weeks apart produce sustained improvement in many patients with moderate to severe MGD.

Thermal pulsation devices (LipiFlow) deliver controlled heat and pressure to the inner eyelid to express inspissated meibum. The effect can last six to twelve months and is repeatable.

Punctal plugs block the drainage of tears from the ocular surface. They are appropriate for aqueous deficient dry eye when lubrication alone is inadequate. Dissolvable collagen plugs are trialled before permanent silicone plugs are inserted.

Treatment	Best For	Time to Effect
Preservative-free lubricants	All types, daily use	Immediate symptom relief
Lid hygiene + warm compresses	Evaporative / MGD	4 to 8 weeks of daily use
Omega-3 supplementation	Evaporative / MGD	8 to 12 weeks
Cyclosporine drops	Inflammatory DED	3 to 6 months
Lifitegrast drops	Inflammatory DED	2 to 4 weeks for symptoms
IPL therapy	Moderate to severe MGD	After 3 to 4 sessions
Punctal plugs	Aqueous deficient DED	Days to weeks

Monitoring Dry Eye Over Time

Dry eye is managed, not cured. Follow-up visits every three to six months allow the specialist to assess treatment response, adjust the regimen, and monitor for corneal surface deterioration.

Objective tests — TBUT, osmolarity, staining scores — are more reliable than symptoms alone. Patients often adapt to chronic discomfort and underreport severity. Imaging guides clinical decisions even when symptoms appear stable.

Meibomian gland dropout is irreversible. Preventing further loss is the priority once significant atrophy is identified.

Dry Eye and Systemic Disease

Dry eye is frequently a signal of systemic disease. Sjogren’s syndrome, rheumatoid arthritis, lupus, thyroid eye disease, and graft-versus-host disease all affect the ocular surface. Patients with unexplained severe dry eye — particularly younger women — should be evaluated for autoimmune conditions.

Conversely, patients already diagnosed with these conditions should have formal ocular surface assessments. Dry eye in this context needs co-management with the treating physician.

When to See a Glaucoma and Ocular Surface Specialist

Many patients with dry eye also have glaucoma or glaucoma suspect status. Glaucoma drops — particularly those with preservatives — are a significant cause of ocular surface disease. The benzalkonium chloride (BAK) in most preserved glaucoma drops is toxic to goblet cells and the corneal epithelium.

If you use glaucoma drops and have dry eye symptoms, your specialist needs to review both conditions together. Switching to preservative-free formulations or fixed-combination drops can reduce surface toxicity without compromising IOP control.

A specialist with expertise in both conditions can optimise your glaucoma management while actively protecting the ocular surface.

Known for her structured approach to glaucoma risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online.

Frequently Asked Questions

Can dry eye disease be cured?

There is no permanent cure for most forms of dry eye disease. However, it can be very well controlled with the right treatment strategy. Many patients achieve significant symptom relief and stable ocular surface health with long-term management.

Are lubricating drops enough to treat dry eye?

For mild disease, lubricants provide adequate relief. For moderate to severe dry eye — or evaporative disease driven by meibomian gland dysfunction — drops manage symptoms but do not address the underlying cause. Lid hygiene, anti-inflammatory therapy, and sometimes procedural treatment are needed.

How do I know if my dry eye is getting worse?

Worsening symptoms, increased frequency of drop use, morning grittiness, light sensitivity, and fluctuating vision are all signs of progression. Objective worsening on TBUT, staining, or osmolarity testing confirms it. Do not wait for significant discomfort before seeking review.

Can diet help with dry eye?

Yes. Omega-3 fatty acids from oily fish, flaxseed, and walnuts support meibomian gland secretion quality. Adequate hydration matters. Foods high in omega-6 fatty acids and processed vegetable oils may worsen inflammation. A Mediterranean-style diet is broadly supportive of ocular surface health.

Is dry eye related to screen use?

Yes. Screen use reduces spontaneous blink rate from a normal 15 to 17 blinks per minute to as few as 3 to 5 blinks per minute. Reduced blinking causes tear film instability and accelerates evaporation. Deliberate blinking exercises and regular screen breaks are first-line recommendations for screen-related dry eye.

Can I wear contact lenses if I have dry eye?

Some patients with well-managed mild dry eye can wear contacts with modifications — daily disposable lenses, lubricating drops compatible with contact wear, and reduced wearing time. Patients with moderate to severe dry eye are advised to avoid contact lenses until surface health is restored. Scleral lenses are a specialist option for severe cases.

Does menopause cause dry eye?

Yes. Oestrogen and androgen deficiency after menopause reduces both aqueous and meibomian secretion. Dry eye prevalence in post-menopausal women is significantly higher than in age-matched men. Hormone replacement therapy has a complex relationship with dry eye — some studies show benefit, others do not. Ocular surface assessment after menopause is advisable.

Book a Dry Eye Assessment in Gurgaon

Dry eye responds best to early, structured management. A thorough ocular surface assessment — including meibography, osmolarity, and staining — identifies the cause and guides a treatment plan that works long-term.

If you are using lubricating drops daily and still struggling, the underlying mechanism has not yet been addressed. A specialist review changes that.

About the Author

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

Access her work on Pubmed, Google Scholar, ResearchGate and ORCID.

Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care

www.drshibalbhartiya.com
+91 88826 38735

1500+ Five Star Patient Reviews Google Business Profile

Upload your reports for a structured review.

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Basics of Dry Eye

Dry Eye Second Opinion

Dry Eye: A Chronic Disease

Why Do Women Get Dry Eye More Often?

Menopause and Dry Eye

Dry Eyes: Natural Remedies